Drug Profile
Pabinafusp alfa - JCR Pharmaceuticals
Alternative Names: IZCARGO; JR 141; Recombinant iduronate-2-sulfatase - JCR Pharmaceuticals; TAK-141Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Class Antibodies; Iduronate sulfatases; Recombinant fusion proteins
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis II
Most Recent Events
- 06 Apr 2023 JCR Pharmaceuticals and Sumitomo Pharma agree to co-promote pabinafusp alfa in Japan for Mucopolysaccharidosis-II
- 27 Mar 2023 Pabinafusp alfa is available on a Named Patient Access Programme for the treatment of Mucopolysaccharidosis II in countries where it is not commercially available
- 22 Feb 2023 JCR Pharmaceuticals initiates enrolment by invitation in a phase III trial for Mucopolysaccharidosis II (In children, In adolescents, In adult, In the elderly) in USA (IV) (NCT05594992)